Noven Announces Earnings Release Date And Upcoming Investor Conference Presentation

-- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced its full-year 2003 earnings release date as well as a scheduled investor conference presentation.

On February 26, before the market opens, Noven is scheduled to issue a press release announcing its financial results for the year and quarter ended December 31, 2003. At 10:00 a.m. Eastern Time the same day, a conference call among management and analysts will be broadcast live via the Internet at www.noven.com, and a rebroadcast will be accessible at the same site. A taped replay of the call will be available by telephone beginning in the afternoon of February 26 through February 28 by calling 877-660-6853 (from within the U.S.) or 201-612-7415 (from outside the U.S.) and entering the account code 1628 and conference ID# 93644.

Noven also announced that Robert C. Strauss, its President, CEO & Chairman, will present Noven's business and prospects on March 5 at the Lehman Brothers Seventh Annual Global Healthcare Conference in Miami Beach, Florida. Live webcast information for that presentation will be announced when available.

Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Together with Novartis Pharmaceuticals Corporation, Noven owns a profitable women's health products company called Novogyne Pharmaceuticals. Noven's existing products include advanced estrogen transdermal delivery systems (including Vivelle-Dot®, licensed to Novogyne, and Estradot®, licensed to Novartis Pharma AG) and combination estrogen/progestin transdermal delivery systems (including CombiPatch®, licensed to Novogyne, and Estalis®, licensed to Novartis Pharma AG). With a range of innovative transdermal products in development, Noven is committed to remaining one of the world’s premier transdermal drug delivery companies. For further information on Noven visit www.noven.com.

Contact:
Investor & Media Contact

Joseph C. Jones
Vice President – Corporate Affairs
Noven Pharmaceuticals, Inc.
305-253-1916